Reviewer's report

Title: A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure

Version: 4  Date: 7 October 2014

Reviewer: Brenda Banwell

Reviewer's report:

The authors provide a view of the tolerability of Fingolimod in an ambulatory setting in Swiss MS clinics. The paper is concise and well-written.

Major Compulsory Revisions:

Abstract - is concise and to the point; however, the abstract doesn't sell the article and doesn't explain why this article is important or needs to be read

Methods and Results

The authors should contrast the international monitoring recommendations with those in place in Switzerland. It is unclear how these differ.

The authors focus almost entirely on the cardiac monitoring and only report cardiac side effects. They should discuss the full spectrum of potential toxicities and report on how many patients had retinal changes, infection, and specifically herpes re-activation.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have served as a reviewer of pediatric MS protocols for Novartis, Sanofi-Aventis, Biogen-IDEC, and Teva Neuroscience. I do not receive any financial remuneration for this work.

I am a centralized MRI reviewer for Novartis, and am compensated for this effort.